News Oxford BioMedica could get $100m following CAR-T approval UK biotech will supply key component of Novartis' newly approved cancer cell therapy
News Oxford BioMedica signs $100m CAR-T deal with Novartis UK firm to supply viruses to generate CAR-T therapies